Examkin

Soru

Zorluk: ZorPsychopharmacology and Psychological Therapies

A 28-year-old male with a 5-year history of schizophrenia is evaluated in the inpatient psychiatric unit for severe, persistent commanding auditory hallucinations and paranoid delusions. He is currently prescribed olanzapine 20 mg daily. His psychiatric history reveals a prior 8-week trial of risperidone 6 mg daily, which was discontinued due to a lack of efficacy. The patient insists he takes his medication every day as prescribed. The treatment team is evaluating him for treatment-resistant schizophrenia. Arrange the following management steps in the most appropriate chronological sequence for this patient.

  1. 1Objectively verify medication adherence using plasma drug levels or strictly observed administration.
  2. 2Obtain a baseline absolute neutrophil count (ANC) and register the patient in the clozapine Risk Evaluation and Mitigation Strategy (REMS) program.
  3. 3Initiate clozapine therapy with a gradual upward dose titration.
  4. 4Conduct weekly absolute neutrophil count (ANC) monitoring for the first six months of therapy.
  5. 5Consider electroconvulsive therapy (ECT) or antipsychotic augmentation if psychotic symptoms remain refractory.

Cevap

The optimal sequence is: 1) Verify adherence, 2) Obtain baseline ANC and complete REMS registration, 3) Initiate clozapine with slow titration, 4) Monitor ANC weekly for six months, 5) Consider ECT or augmentation for clozapine-refractory symptoms.
The correct sequence follows the standard psychiatric algorithm for suspected treatment-resistant schizophrenia (failure of two antipsychotics). Adherence must be verified first to rule out pseudo-resistance. Once true resistance is established, clozapine is the drug of choice. Due to the risk of life-threatening agranulocytosis, baseline ANC and REMS registration must precede initiation. Clozapine is then started with a slow dose titration, followed by mandatory weekly ANC monitoring for the first six months. If clozapine fails, ECT or augmentation (clozapine-refractory management) is the final step.

Adım Adım Çözüm

1
Rule out pseudo-resistance.
Medication adherence is objectively verified.
Non-adherence is the most common cause of apparent treatment failure in schizophrenia. It must be ruled out before escalating to clozapine.
2
Prepare for clozapine initiation.
Baseline ANC is obtained and REMS registration is completed.
Clozapine carries a black-box warning for severe neutropenia; baseline labs and federal REMS registry enrollment are prerequisites for prescription.
3
Start clozapine pharmacotherapy.
Clozapine is initiated and titrated slowly.
A slow titration schedule is required to mitigate the risk of adverse cardiovascular events and dose-dependent seizures.
4
Maintain clozapine safety monitoring protocols.
Weekly ANC monitoring is conducted for 6 months.
REMS protocol mandates weekly blood draws for the first 6 months to detect agranulocytosis early and ensure patient safety.
5
Address clozapine-resistant schizophrenia.
ECT or augmentation strategies are considered.
If a patient fails clozapine monotherapy, they are considered clozapine-refractory, and more invasive or combinatory treatments are warranted.

Anahtar Kavram

Algorithm for Treatment-Resistant Schizophrenia
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Psychopharmacology and Psychological Therapies

Bu konudan daha fazla soru